Human Trials

AbbVie’s psoriasis drug meets co-primary endpoints in three phase 3 trials

AbbVie’s psoriasis drug risankizumab has met all co-primary and ranked secondary points in three pivotal phase 3 clinical trials.

Novartis pediatric multiple sclerosis drug Gilenya shows significant effect in phase III trial

Novartis has announced full results from the phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) versus interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

Study uses genomics to make treatment recommendations for recurrent glioblastoma patients

A study led by the Translational Genomics Research Institute (TGen), UC San Francisco (UCSF) and the Ivy Foundation Early Phase Clinical Trials Consortium has used genomics to make treatment recommendations for recurrent glioblastoma patients.

Gilead Sciences’ GS-0976 shows positive effect in phase 2 NASH study

Gilead Sciences announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH).

Pfizer’s lung cancer drug lorlatinib succeeds in phase 2 trial

Pfizer says that its investigational, next-generation tyrosine kinase inhibitor lorlatinib showed clinically meaningful activity against lung tumors and brain metastases in a phase 2 trial in patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC).

miRagen Therapeutics reports positive clinical data of MRG-106 in patients with mycosis fungoides form of cutaneous T-cell lymphoma

miRagen Therapeutics has announced new interim results from its ongoing phase 1 clinical trial evaluating the safety, efficacy and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

Human clinical trial commences for first leprosy vaccine candidate

The Infectious Disease Research Institute (IDRI) and American Leprosy Missions have started a Phase 1 clinical trial in humans for leprosy vaccine candidate, the first vaccine developed specifically for leprosy.

Ardelyx’s phase 3 study of Tenapanor for IBS-C meets primary endpoint

Ardelyx has released positive results from its second Phase 3 study of tenapanor, dubbed T3MPO-2, for irritable bowel syndrome with constipation (IBS-C).

Bayer, Janssen halt phase III ESUS study of anticoagulant medicine Xarelto

Bayer, along with its development partner Janssen Research & Development, has halted the phase III Navigate ESUS study of rivaroxaban (Xarelto), as it demonstrated comparable efficacy between treatment arms.